as 06-05-2025 4:00pm EST
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Founded: | 2000 | Country: | United States |
Employees: | N/A | City: | LEXINGTON |
Market Cap: | 21.3M | IPO Year: | 2000 |
Target Price: | $16.50 | AVG Volume (30 days): | 78.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.03 | EPS Growth: | N/A |
52 Week Low/High: | $1.02 - $9.78 | Next Earning Date: | 07-31-2025 |
Revenue: | $11,202,000 | Revenue Growth: | 14.17% |
Revenue Growth (this year): | 0.93% | Revenue Growth (next year): | 8.10% |
CRIS Breaking Stock News: Dive into CRIS Ticker-Specific Updates for Smart Investing
GOBankingRates
6 days ago
GOBankingRates
6 days ago
GOBankingRates
6 days ago
Yahoo Finance
6 days ago
The Guardian
6 days ago
Yahoo Finance Video
6 days ago
Benzinga
6 days ago
Reuters
6 days ago
The information presented on this page, "CRIS Curis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.